Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
OBJECTIVE
The objective of this analysis was the evaluation of the outcomes and costs associated with rivaroxaban and enoxaparin for the prevention of postsurgical venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) and total knee replacement (TKR) from the US payer perspective.


METHODS
VTE event rates have been reported in three Phase III clinical trials that compared rivaroxaban and enoxaparin for VTE prevention after orthopedic surgery during the prophylaxis (≤35 days for THR patients and 10-14 days for TKR patients) and post-prophylaxis periods (≤90 days following surgery). These data were used in this decision-analytic model to estimate and compare health outcomes and costs associated with rivaroxaban and enoxaparin. The base-case analysis considered the number and costs of symptomatic VTE events during the prophylaxis period only. A 90-day horizon was considered in the sensitivity analysis.


RESULTS
Following THR, when extended durations of prophylaxis (35 days) were compared, rivaroxaban was associated with lower costs than enoxaparin, with total saving costs of $695/patient. When an extended duration of rivaroxaban prophylaxis (35 days) was compared with a short duration (10-14 days) of enoxaparin prophylaxis, rivaroxaban was estimated to prevent 9.9 additional symptomatic VTE events per 1000 patients, while saving $244/patient (rate/1000 patients). In the TKR population, short duration of rivaroxaban prophylaxis was estimated to prevent 13.1 additional symptomatic VTE events per 1000 patients. It was also less costly than short duration enoxaparin prophylaxis, with a saving of $411/patient (rate/1000 patients).


CONCLUSIONS
Only statistically significant differences were captured in the base-case economic analysis, and, therefore, differences in pulmonary embolism (PE) and bleeding events were not captured.


CONCLUSIONS
In this model, rivaroxaban reduced total treatment payer costs vs enoxaparin for the prevention of VTE in THR or TKR patients.
IMS Health, London, UK.
Aurea
A
Duran
Nishan
N
Sengupta
Alexander
A
Diamantopoulos
Fiona
F
Forster
Louis
L
Kwong
Michael
M
Lees
D000925:Anticoagulants / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip / Q000379:methods; D019645:Arthroplasty, Replacement, Knee / Q000379:methods; D017326:Clinical Trials, Phase III as Topic; D003365:Costs and Cost Analysis; D017984:Enoxaparin / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D006296:Health Services / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D014481:United States; D054556:Venous Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban